BIIB080 is currently being evaluated in Phase II as a treatment for patients in the early stages of Alzheimer's disease. It is an oligonucleotide targeting the tau protein, which is associated with changes in the brain linked to Alzheimer's disease.
In early stage clinical studies, BIIB080 has shown positive results by reducing tau protein l...
Tau-targeted Alzheimer's drug gets Fast Track designation in the USA
Biogen's Alzheimer's candidate BIIB080 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).
Vill du få åtkomst till allt?
Prova 30 dagar för 0 kr.
Inga bindningstider eller kortuppgifter krävs.
Prova nu
Köp en prenumeration
Utforska våra prenumerationslösningar och välj den som passar dina behov.
Välj din prenumeration